Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)
Abstract There is considerable potential for integrating transarterial chemoembolization (TACE), programmed death-(ligand)1 (PD-[L]1) inhibitors, and molecular targeted treatments (MTT) in hepatocellular carcinoma (HCC). It is necessary to investigate the therapeutic efficacy and safety of TACE comb...
Shranjeno v:
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Artigo |
Jezik: | angleščina |
Izdano: |
2023
|
Online dostop: | https://doi.org/10.1038/s41392-022-01235-0 https://www.nature.com/articles/s41392-022-01235-0.pdf |
Oznake: |
Označite
Brez oznak, prvi označite!
|